
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a promising biotechnology company with a positive outlook, thanks to their innovative Dually Derivatized Oligochitosan (DDX) platform and current focus on developing a mucosal gene therapy for Non-Muscle Invasive Bladder Cancer (NMIBC). Detalimogene, their lead candidate, has shown potential with a 54% any-time complete response rate and a low incidence of treatment-related adverse events, making it a strong candidate for FDA approval. The company also has a potential upside with their combination of detalimogene and surfactant bladder wash, which has shown improved transfection and higher expression of IL-12. Investors will be looking for an update on the durability of the response to detalimogene in late 2026 to further assess the commercial potential of the drug.
Bears say
enGene Therapeutics is facing significant financial challenges due to its high operating expenses and low cash reserves. The company's net loss has increased, driven by higher operating expenses, and its cash, cash equivalents, and marketable securities are limited. Additionally, while enGene's non-viral gene therapy platform shows potential in the NMIBC market, its competitors have more promising data and it remains to be seen how the FDA and payers will view the company's product. These uncertainties make it difficult to have a positive outlook on the company's stock.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares